BRNS Stock Analysis: Buy, Sell, or Hold?
BRNS - Barinthus Biotherapeutics plc American Depositary Shares
$0.66
0.06 (9.43%)
▲
5d:
+6.45%
30d:
+9.82%
90d:
-3.93%
WAIT
LOW Confidence
Analysis Updated: Aug 25, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When BRNS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BRNS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BRNS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: BRNS is currently trading at $0.66, which is considered extended relative to its 30-day fair value range of $0.57 to $0.62.
Technical Outlook: Technically, BRNS is showing sideways momentum. Immediate support is located at $0.55, while resistance sits at $0.68. The stock is showing strong short-term momentum, up 9.4% recently.
Market Sentiment: BRNS scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.00 (+657.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BRNS is showing sideways momentum. Immediate support is located at $0.55, while resistance sits at $0.68. The stock is showing strong short-term momentum, up 9.4% recently.
Market Sentiment: BRNS scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.00 (+657.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.57 -
$0.62
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range (+6.5% above its trading range)
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.4%)
- BULLISH: Trading 657.6% below Wall St target ($5.00)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.57 -
$0.62
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.55
Resistance Level
$0.68
Current Trend
Sideways
Technical data as of
Aug 25, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.55
Wall Street Target
$5.00
(+657.6%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 25, 2026 5:13 PM ET
Data refreshes hourly during market hours. Next update: 6:13 PM
Data refreshes hourly during market hours. Next update: 6:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BRNS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 32 SELL |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$560 | 32 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
